ClinicalTrials.Veeva

Menu
C

Clinical Trials Research Institute | Thousand Oaks, CA

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Upadacitinib
Dupilumab
Difamilast
Lutikizumab
PP405
Spesolimab
RPT193
Risankizumab
Povorcitinib

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

12 of 16 total trials

A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up)

Atopic dermatitis (AD) is a skin condition that may cause a rash and itching due to inflammation of the skin. Therapies spread over the skin may not...

Enrolling
Atopic Dermatitis
Drug: Upadacitinib Dose B
Drug: Upadacitinib Dose A

Vitiligo is a common chronic autoimmune disease that causes the body's immune system to attack its own pigment producing skin cells. This study is to...

Invitation-only
Vitiligo
Drug: Upadacitinib
Drug: Placebo

Hidradenitis suppurativa (HS) is an inflammatory skin disease that causes painful lesions in the axilla (underarm), inguinal (groin) and anogenital (...

Enrolling
Hidradenitis Suppurativa
Drug: Upadacitinib
Drug: Placebo

Hidradenitis suppurativa (HS) is a chronic and often painful inflammatory skin disease which includes the forming of lumps, abscesses and scars in ar...

Enrolling
Hidradenitis Suppurativa
Drug: Lutikizumab
Drug: Placebo

Hidradenitis suppurativa (HS) is a chronic and often painful inflammatory skin disease which includes the forming of lumps, abscesses and scars in ar...

Active, not recruiting
Hidradenitis Suppurativa
Drug: Placebo
Biological: Lutikizumab
Locations recently updated

This study is being conducted to determine the efficacy and safety of povorcitinib in participants with nonsegmental vitiligo.

Enrolling
NonSegmental Vitiligo
Drug: Povorcitinib
Drug: Placebo

Alopecia areata (AA) is a disease that happens when the immune system attacks hair follicles and causes hair loss. AA usually affects the head and fa...

Enrolling
Alopecia Areata
Drug: Upadacitinib
Drug: Placebo

This study is open to people with hidradenitis suppurativa (HS) who have completed another study with spesolimab (study 1368-0098 (NCT05819398) or st...

Active, not recruiting
Hidradenitis Suppurativa (HS)
Drug: Spesolimab

This study is open to adults with moderate to severe hidradenitis suppurativa (HS). The purpose of this study is to find out whether a medicine calle...

Active, not recruiting
Hidradenitis Suppurativa
Drug: Placebo matching Spesolimab Formulation 1
Drug: Placebo matching Spesolimab Formulation 2

The purpose of this study is to evaluate the safety and tolerability of XmAb27564 following multiple doses among participants with plaque psoriasis a...

Active, not recruiting
Atopic Dermatitis
Psoriasis
Biological: XmAb27564
Biological: Placebo

The study is designed to validate safety results from the Phase 1 PP405-001 trial while also characterizing longer term safety and PK following 28 da...

Active, not recruiting
Androgenetic Alopecia
Drug: PP405 Topical Vehicle Gel
Drug: PP405 0.05% Topical Gel

Psoriasis (PsO) is a chronic disease characterized by marked inflammation of the skin that results in thick, red, scaly plaques. This study will asse...

Active, not recruiting
Scalp Psoriasis
Genital Psoriasis
Drug: Risankizumab
Drug: Placebo for Risankizumab

Trial sponsors

AbbVie logo
Acrotech Biopharma logo
Boehringer Ingelheim logo
Incyte logo
RAPT Therapeutics logo
Xencor logo
P

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems